

ELECTRONIC FILE DATE: 27 NOVEMBER 2007

Attorney Docket No. PG3600USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Farrow, *et al.*

Serial No.: 09/868,533

Group Art Unit No.: 1652

Filed: 21 September 2001

Examiner: Mondesi, Robert B.

For: MEMBER OF THE TNF LIGAND FAMILY

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper.

All of the references cited herein came to the Applicants' attention when they were cited in the following two European Oppositions: (1) an EPO Opposition filed by Human Genome Sciences and Serono against Biogen IDEC's EP Patent No. 1146892; and (2) an EPO Opposition filed by Human Genome Sciences, Corixa Corp., Genentech, and Biogen IDEC against Zymogenetics' EP Patent No. 1141274. Both EP Patent Nos. EP1146892 and EP1141274 disclose polypeptide sequences relating to the TNF ligand superfamily member recited in the instantly pending claims.

This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Elizabeth J. Hecht

Attorney for Applicants

Registration No. 41,824

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-5009/Facsimile (610) 270-5090

n:\ejh\applns\p cases_pg\pg3600\pg3600usw\rcelidsstatement.doc